![]() |
Name |
Sporulactone D
|
Molecular Formula | C14H18O6 | |
IUPAC Name* |
3-(1-hydroxyethyl)-3-(hydroxymethyl)-5,7-dimethoxy-4-methyl-2-benzofuran-1-one
|
|
SMILES |
COc1cc(OC)c2c(c1C)C(CO)(C(C)O)OC2=O
|
|
InChI |
InChI=1S/C14H18O6/c1-7-9(18-3)5-10(19-4)11-12(7)14(6-15,8(2)16)20-13(11)17/h5,8,15-16H,6H2,1-4H3/t8-,14+/m1/s1
|
|
InChIKey |
NCGKGGQMMSEWEC-CLAHSXSESA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 282.29 | ALogp: | 0.8 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 85.2 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.806 |
Caco-2 Permeability: | -4.839 | MDCK Permeability: | 0.00001200 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.09 |
Human Intestinal Absorption (HIA): | 0.037 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.011 |
Blood-Brain-Barrier Penetration (BBB): | 0.967 | Plasma Protein Binding (PPB): | 40.30% |
Volume Distribution (VD): | 1.114 | Fu: | 37.62% |
CYP1A2-inhibitor: | 0.147 | CYP1A2-substrate: | 0.787 |
CYP2C19-inhibitor: | 0.025 | CYP2C19-substrate: | 0.897 |
CYP2C9-inhibitor: | 0.01 | CYP2C9-substrate: | 0.432 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.465 |
CYP3A4-inhibitor: | 0.063 | CYP3A4-substrate: | 0.558 |
Clearance (CL): | 6.383 | Half-life (T1/2): | 0.667 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.129 |
Drug-inuced Liver Injury (DILI): | 0.155 | AMES Toxicity: | 0.237 |
Rat Oral Acute Toxicity: | 0.088 | Maximum Recommended Daily Dose: | 0.032 |
Skin Sensitization: | 0.05 | Carcinogencity: | 0.027 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.046 |
Respiratory Toxicity: | 0.074 |